SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Munch-a-Biotech Today -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (1046)6/13/2001 11:55:47 AM
From: tommysdad  Respond to of 3158
 
1) Rick-- welcome back.

2) This was not a good deal for CRA. AXPH does not have a history of success. One could blame it on the targets, I suppose, but I blame it on the chemistry. They just made bad molecules and subsequent bad choices. I don't see how CRA is going to fix that.



To: scaram(o)uche who wrote (1046)6/13/2001 11:56:39 AM
From: Pierre Borczuk  Respond to of 3158
 
error sorry



To: scaram(o)uche who wrote (1046)6/13/2001 11:56:40 AM
From: Pierre Borczuk  Read Replies (1) | Respond to of 3158
 
is LYNX munchable?

I noticed some insider buys



To: scaram(o)uche who wrote (1046)6/14/2001 1:18:46 AM
From: Larry Liebman  Read Replies (1) | Respond to of 3158
 
A lifetime ago, I owned Sequana before Arris munched them and metamorphosed into AXPH. I no longer remember what they did with SQNA, but I wondered if that early genomic research, not withstanding the current chemists or "pipeline", played any role in the CRA acquisition. Whatever the rationale, what a pathetic end to such a promising company, i.e., you could have held it for 10 years for a stunning return of $4.65.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News